Strategic partnerships Emery Pharma has ongoing collaborations with Centivax, GenNext Technologies, Telo Genomics, and Vertosa, indicating a strong track record in forming technology-driven CRO partnerships. Opportunity: target emerging biotech firms and vaccine developers seeking GLP/CGMP compliant analytics and bioanalytical support.

Clinical program support With experience spanning from early preclinical to Phase 3, Emery Pharma can position as a one-stop CRO for end-to-end drug development analytics, bioanalysis, and microbiology. Opportunity: upsell integrated analytical services to sponsors advancing complex clinical programs.

Regulatory readiness Facility maintains FDA registration, DEA licensure, and cGMP/GLP compliance, underscoring reliability for regulated projects. Opportunity: pursue clients needing compliant GLP testing, method development/validation, and regulatory-ready data packages.

Analytical capabilities Advanced LCMS-MS, NMR, HPLC, GC-MS, and microbiology testing capabilities support diverse test menus, including bioanalytical and antibacterial/antifungal profiling. Opportunity: target companies requiring robust analytical chemistry and microbial testing for biologics, small molecules, and vaccine candidates.

Market expansion Recent client wins and high-profile partnerships in biopharma and biotech suggest growth momentum in the San Francisco Bay Area and globally. Opportunity: leverage success stories to reach mid-size biotech firms and early-stage vaccine/development programs seeking regional CRO support with global reach.